Eisai Co

Eisai Co Equity

The The Equity of Eisai Co (4523.T) as of Nov 15, 2026 is 898.99 B JPY. In the previous year, The Equity was 841.42 B JPY — a change of 6.84% (higher).

Equity

898.99 BJPY

YoY

6.84%

Last updated:

In 2026, Eisai Co's equity was 898.99 B JPY, a 6.84% increase from the 841.42 B JPY equity in the previous year.

The Eisai Co Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2019
628.12 B JPY
Jan 1, 2020
678.13 B JPY
Jan 1, 2021
703.18 B JPY
Jan 1, 2022
748.82 B JPY
Jan 1, 2023
799.96 B JPY
Jan 1, 2024
875.61 B JPY
Jan 1, 2025
841.42 B JPY
Jan 1, 2026
898.99 B JPY
The Eisai Co Equity history
YEAREquityYoY
898.99 BJPY+6.84%
841.42 BJPY-3.91%
875.61 BJPY+9.46%
799.96 BJPY+6.83%
748.82 BJPY+6.49%
703.18 BJPY+3.69%
678.13 BJPY+7.96%
628.12 BJPY+5.82%
593.58 BJPY+1.53%
584.63 BJPY+1.91%
573.66 BJPY-4.19%
598.75 BJPY+13.76%
526.32 BJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Eisai Co Stock analysis

What does Eisai Co do? Eisai Co Ltd is a Japanese pharmaceutical company based in Tokyo that specializes in research, development, production, and marketing of pharmaceuticals. The company was founded in 1936 by Shinjiro Torii, who had previously worked as a chemist at another pharmaceutical company. Eisai began its journey in the production of medicines, especially herbal medicine known in Japan, which are sold as OTC products. Eisai grew rapidly and started producing antibiotics in 1947. Over the following decades, the company expanded into the global market and is now present in over 20 countries. Eisai is dedicated to creating innovations as its main business model in order to help patients worldwide through its range of products. With this mission, the company has developed and introduced hundreds of drugs to the market, improving the quality of life for millions of people around the world. The company is divided into several business segments, including neurology, oncology, coagulation disorders, and gastrointestinal diseases. Eisai specializes in developing innovative drugs targeting a wide range of human diseases. Eisai is particularly known today for its leading position in Alzheimer's and dementia research. An important milestone in the company's history was the discovery of Aricept, a medication used to treat Alzheimer's disease. Eisai was the first Japanese company to develop a drug approved by the US FDA. Other products from Eisai include Lenvima, a medication for the treatment of thyroid cancer, and Lusedra, a sedative for anesthesia induction and maintenance for patients undergoing surgery. Eisai invests significantly in research and development to maintain its position as an innovation leader in the pharmaceutical manufacturing industry. The company collaborates with leading academic institutions and research organizations to make groundbreaking discoveries in various medical fields. Eisai also places importance on social responsibility and is involved in numerous social projects such as supporting Japan against cancer and providing consultation for elderly home care. The company aims to contribute to making the healthcare system more sustainable and equitable. Overall, Eisai is a leading pharmaceutical company with a strong focus on creating innovations to improve human health. It has a wide range of products and continuously works on developing new drugs and therapies to help patients worldwide. Eisai Co is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Eisai Co's Equity

Eisai Co's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Eisai Co's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Eisai Co's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Eisai Co's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Eisai Co’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Eisai Co stock

The Equity of Eisai Co is 898.99 B JPY in 2026.

The Equity of Eisai Co changed from 841.42 B JPY to 898.99 B JPY, representing a 6.84% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity Eisai Co since 2006 – with annual values, charts, and detailed analysis.

The Equity's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Eisai Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Eisai Co

All Key Metrics — Eisai Co